Professor Cerullo was recognised for his seminal contributions to oncolytic immunotherapies, particularly the development of PeptiCRAd technology—a novel method that decorates oncolytic virus capsids with cancer-specific peptides. This innovation enables the rapid creation of personalised cancer treatments, offering new hope for patients worldwide.
Beyond his academic achievements, Cerullo was commended for his commitment to translating research into real-world impact. He founded Valo Therapeutics, a spin-out company dedicated to advancing PeptiCRAd technology. The company’s lead product is currently in Phase I clinical trials, a notable milestone for a complex advanced therapy medicinal product (ATMP) involving different components including live viruses.
Presenting the award, the Society’s president praised Cerullo’s dual dedication to scientific excellence and societal benefit, calling the recognition both a professional honor and a personal pleasure.